---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000053"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:16:02.848594+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aerovate Q2 net loss $19.0M; cash $150.1M; ATM raised $45M; Phase 2b/3 PAH trial on track

## Summary
- Net loss of $19.0M for Q2 2023 vs $12.0M in Q2 2022; includes $3.0M stock comp.
- Cash, cash equivalents and available-for-sale securities total $150.1M; runway extended into 2026.
- Sold $45M common stock under ATM program; proceeds fund operations.
- IMPAHCT Phase 2b/Phase 3 trial for AV-101 in PAH has >110 sites active in >20 countries; topline data expected Q2 2024.
- Appointed Habib Dable (ex-Acceleron CEO) to Board of Directors.

## SEC filing metadata
- accession: 0001798749-23-000053
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/0001798749-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/tmb-20230814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000053
- JSON: https://secwatch.observer/filing/0001798749-23-000053.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000053.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/0001798749-23-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.